Test an immune marker in primary Sjögren’s disease activity
Treatments studied
Part of Bones, joints & muscles, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This study looks at an immune reaction (called anti-Ro/SSA IgE) to see how active primary Sjögren’s disease is. It may help doctors better understand what’s driving symptoms and activity levels over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have primary Sjögren’s syndrome (not Sjögren’s caused by another condition)
- You can read, understand, and sign the study consent form
- You’re willing and able to return for all required follow-up visits and exams
- You do not have other major autoimmune diseases (for example rheumatoid arthritis or ANCA vasculitis)
- You have not taken certain immune-targeting medicines in the last 6 months (including abatacept, sifalimumab, rontalizumab, anifrolumab, belimumab, TNF blockers, or interferon)
- You do not have signs or symptoms of an active infection right now
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called ICP-488 for people with primary Sjögren's syndrome (the main form, not caused by other conditions). The goal is to see if the drug can help control symptoms better than a placebo. Participants must have active disease and stable treatment.
This study follows adults with primary Sjögren’s syndrome. It may help researchers understand the condition better by using information from people who have already joined the earlier ASSESS study.
This trial tests an experimental drug, IMVT-1402, in adults with primary Sjogren's disease who have moderate to severe symptoms. The goal is to see if it can reduce disease activity safely.
This trial studies whether iguratimod improves symptoms in people with primary Sjögren’s syndrome, and checks how safe it is. It focuses on people with confirmed disease markers (anti-SSA/Ro-60) and ongoing dry eyes and dry mouth.
This study looks at people with primary Sjögren's syndrome who have had a blood test for a specific antibody called anti-Ro52. The goal is to understand how antibody levels relate to the disease course and help predict outcomes.
This Phase 2 study tests how to measure changes in primary Sjögren’s syndrome symptoms and body activity. It may help researchers confirm which outcomes best reflect improvement and how different patient types respond to treatment.
Hear when a new Primary Sjögren's Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.